Podcasts about rociletinib

Play Episode Listen Later Apr 20, 2016 5:20

Dr. Jack West, Swedish Cancer Institute, reviews trial evidence for the efficacy of rociletinib and osimertinib for EGFR acquired resistance not driven by a T790M mutation.

west cancer institute resistance negative swedish lung acquired egfr nsclc jack west osimertinib gracecast t790m cancergrace swedish cancer institute necitumumab gcvl gcvllung azd9291 rebiopsy co1686 rociletinib

Rociletinib/Osimertinib for EGFR T790M-negative NSCLC

Play Episode Listen Later Apr 20, 2016 5:20

Dr. Jack West, Swedish Cancer Institute, reviews trial evidence for the efficacy of rociletinib and osimertinib for EGFR acquired resistance not driven by a T790M mutation.

west cancer institute resistance negative swedish lung acquired egfr nsclc jack west osimertinib gracecast t790m cancergrace swedish cancer institute necitumumab gcvl gcvllung azd9291 rebiopsy co1686 rociletinib

Third Generation EGFR TKIs for Acquired Resistance

Play Episode Listen Later Feb 17, 2016 3:07

Dr. Nathan Pennell, Cleveland Clinic, discusses the concept of acquired resistance and new agents designed to address it, including Rociletinib and Merelitinib.

cancer generation stage resistance iv lung mutation acquired cleveland clinic inhibitors egfr third generation nsclc pennell egfr tkis gracecast t790m cancergrace acquired resistance nathan pennell tarceva iressa gcvl gcvllung azd9291 gilotrif rociletinib merelitinib

Third Generation EGFR TKIs for Acquired Resistance

Play Episode Listen Later Feb 17, 2016 3:07

Dr. Nathan Pennell, Cleveland Clinic, discusses the concept of acquired resistance and new agents designed to address it, including Rociletinib and Merelitinib.

cancer generation stage resistance iv lung mutation acquired cleveland clinic inhibitors egfr third generation nsclc pennell egfr tkis gracecast t790m cancergrace acquired resistance nathan pennell tarceva iressa gcvl gcvllung azd9291 gilotrif rociletinib merelitinib

Third Generation EGFR TKIs for Acquired Resistance

Play Episode Listen Later Feb 17, 2016 3:07

Dr. Nathan Pennell, Cleveland Clinic, discusses the concept of acquired resistance and new agents designed to address it, including Rociletinib and Merelitinib.

cancer generation stage resistance iv lung mutation acquired cleveland clinic inhibitors egfr third generation nsclc pennell egfr tkis gracecast t790m cancergrace acquired resistance nathan pennell tarceva iressa gcvl gcvllung azd9291 gilotrif rociletinib merelitinib

Treatment Options for EGFR T790M Negative Acquired Resistance

Play Episode Listen Later Jan 9, 2016 24:36

Dr. Jack West suggests that progression in T790M-negative EGFR lung cancer patients may not require a change in therapy. In this video he details what should go into the decision to modify treatment for those patients.

west cancer institute patients resistance negative swedish forum lung mutation acquired treatment options egfr nsclc jack west osimertinib cetuximab gracecast t790m cancergrace acquired resistance nonsmall erbitux afatinib azd9291 gilotrif th4000 co1686 rociletinib

Treatment Options for EGFR T790M Negative Acquired Resistance

Play Episode Listen Later Jan 9, 2016 24:36

Dr. Jack West suggests that progression in T790M-negative EGFR lung cancer patients may not require a change in therapy. In this video he details what should go into the decision to modify treatment for those patients.

west cancer institute patients resistance negative swedish forum lung mutation acquired treatment options egfr nsclc jack west osimertinib cetuximab gracecast t790m cancergrace acquired resistance nonsmall erbitux afatinib azd9291 gilotrif th4000 co1686 rociletinib

Treatment Options for EGFR T790M Negative Acquired Resistance

Play Episode Listen Later Jan 9, 2016 24:36

Dr. Jack West suggests that progression in T790M-negative EGFR lung cancer patients may not require a change in therapy. In this video he details what should go into the decision to modify treatment for those patients.

west cancer institute patients resistance negative swedish forum lung mutation acquired treatment options egfr nsclc jack west osimertinib cetuximab gracecast t790m cancergrace acquired resistance nonsmall erbitux afatinib azd9291 gilotrif th4000 co1686 rociletinib

Emerging Options for T790M-Positive Acquired Resistance

Play Episode Listen Later Jan 8, 2016 13:53

positive cancer patients resistance options forum memorial emerging lung mutation acquired egfr nsclc sloan kettering mskcc riely gracecast t790m cancergrace acquired resistance erlotinib tarceva nonsmall iressa afatinib gefitinib azd9291 gilotrif co1686 rociletinib

Emerging Options for T790M-Positive Acquired Resistance

Play Episode Listen Later Jan 8, 2016 13:53

positive cancer patients resistance options forum memorial emerging lung mutation acquired egfr nsclc sloan kettering mskcc riely gracecast t790m cancergrace acquired resistance erlotinib tarceva nonsmall iressa afatinib gefitinib azd9291 gilotrif co1686 rociletinib

Emerging Options for T790M-Positive Acquired Resistance

Play Episode Listen Later Jan 8, 2016 13:53

positive cancer patients resistance options forum memorial emerging lung mutation acquired egfr nsclc sloan kettering mskcc riely gracecast t790m cancergrace acquired resistance erlotinib tarceva nonsmall iressa afatinib gefitinib azd9291 gilotrif co1686 rociletinib

Are There Clinically Significant Differences Among the Third Generation EGFR Inhibitors?

Play Episode Listen Later Dec 12, 2015 3:28

Drs. Ben Solomon, Leora Horn, & Jack West compare the clinical data with the third generation EGFR TKIs so active in acquired resistance and consider whether there are significant differences between them.

west resistance differences significant horn drs mutation acquired clinically inhibitors egfr third generation tki jack west osimertinib egfr tkis gracecast t790m wclc cancergrace leora horn azd9291 co1686 rociletinib merelitinib

Are There Clinically Significant Differences Among the Third Generation EGFR Inhibitors?

Play Episode Listen Later Dec 12, 2015 3:28

Drs. Ben Solomon, Leora Horn, & Jack West compare the clinical data with the third generation EGFR TKIs so active in acquired resistance and consider whether there are significant differences between them.

west resistance differences significant horn drs mutation acquired clinically inhibitors egfr third generation tki jack west osimertinib egfr tkis gracecast t790m wclc cancergrace leora horn azd9291 co1686 rociletinib merelitinib

Are There Clinically Significant Differences Among the Third Generation EGFR Inhibitors?

Play Episode Listen Later Dec 12, 2015 3:28

Drs. Ben Solomon, Leora Horn, & Jack West compare the clinical data with the third generation EGFR TKIs so active in acquired resistance and consider whether there are significant differences between them.

west resistance differences significant horn drs mutation acquired clinically inhibitors egfr third generation tki jack west osimertinib egfr tkis gracecast t790m wclc cancergrace leora horn azd9291 co1686 rociletinib merelitinib

Are There Clinically Significant Differences Among the First and Second Generation EGFR TKIs (Iressa, Tarceva, Gilotrif)?

Play Episode Listen Later Dec 8, 2015 3:25

Drs. Ben Solomon, Leora Horn, & Jack West review whether the data and clinical experience suggest any clinically significant differences among the first and second generation EGFR TKIs (Iressa, Tarceva, Gilotrif/Giotrif).

west treatments resistance differences significant horn drs sequence mutation acquired clinically second generation egfr tki jack west osimertinib egfr tkis gracecast t790m wclc cancergrace leora horn tarceva iressa azd9291 gilotrif co1686 rociletinib merelitinib

Are There Clinically Significant Differences Among the First and Second Generation EGFR TKIs (Iressa, Tarceva, Gilotrif)?

Play Episode Listen Later Dec 8, 2015 3:25

Drs. Ben Solomon, Leora Horn, & Jack West review whether the data and clinical experience suggest any clinically significant differences among the first and second generation EGFR TKIs (Iressa, Tarceva, Gilotrif/Giotrif).

west treatments resistance differences significant horn drs sequence mutation acquired clinically second generation egfr tki jack west osimertinib egfr tkis gracecast t790m wclc cancergrace leora horn tarceva iressa azd9291 gilotrif co1686 rociletinib merelitinib

Are There Clinically Significant Differences Among the First and Second Generation EGFR TKIs (Iressa, Tarceva, Gilotrif)?

Play Episode Listen Later Dec 8, 2015 3:25

Drs. Ben Solomon, Leora Horn, & Jack West review whether the data and clinical experience suggest any clinically significant differences among the first and second generation EGFR TKIs (Iressa, Tarceva, Gilotrif/Giotrif).

west treatments resistance differences significant horn drs sequence mutation acquired clinically second generation egfr tki jack west osimertinib egfr tkis gracecast t790m wclc cancergrace leora horn tarceva iressa azd9291 gilotrif co1686 rociletinib merelitinib

Should Third Generation EGFR Inhibitors Be Used Before First Generation EGFR TKIs or After Progression?

Play Episode Listen Later Dec 7, 2015 3:28

Drs. Leora Horn, Ben Solomon, & Jack West consider whether third generation EGFR TKIs, so active in patients with acquired resistance, might be best used prior to development of acquired resistance.

west treatments resistance horn drs progression sequence mutation acquired first generation inhibitors egfr third generation tki jack west osimertinib egfr tkis gracecast t790m wclc cancergrace leora horn azd9291 co1686 rociletinib merelitinib

Should Third Generation EGFR Inhibitors Be Used Before First Generation EGFR TKIs or After Progression?

Play Episode Listen Later Dec 7, 2015 3:28

Drs. Leora Horn, Ben Solomon, & Jack West consider whether third generation EGFR TKIs, so active in patients with acquired resistance, might be best used prior to development of acquired resistance.

west treatments resistance horn drs progression sequence mutation acquired first generation inhibitors egfr third generation tki jack west osimertinib egfr tkis gracecast t790m wclc cancergrace leora horn azd9291 co1686 rociletinib merelitinib

Should Third Generation EGFR Inhibitors Be Used Before First Generation EGFR TKIs or After Progression?

Play Episode Listen Later Dec 7, 2015 3:28

Drs. Leora Horn, Ben Solomon, & Jack West consider whether third generation EGFR TKIs, so active in patients with acquired resistance, might be best used prior to development of acquired resistance.

west treatments resistance horn drs progression sequence mutation acquired first generation inhibitors egfr third generation tki jack west osimertinib egfr tkis gracecast t790m wclc cancergrace leora horn azd9291 co1686 rociletinib merelitinib

Clinical Trial Spotlight: Options for EGFR Mutation-Positive Patients with T790M Mutation-Negative Acquired Resistance

Play Episode Listen Later Nov 20, 2015 3:24

Dr. Jack West reviews treatment options for patients with an EGFR activating mutation and acquired resistance but no T790M mutation, focusing on a clinical trial with the novel hypoxia-induced pan-HER inhibitor TH4000.

growth west positive cancer institute trial patients resistance trials negative options swedish factor clinical lung mutation clinical trials acquired receptor inhibitor egfr nsclc jack west epidermal osimertinib gracecast t790m cancergrace acquired resistance nonsmall azd9291 panher co1686 rociletinib th4000

Clinical Trial Spotlight: Options for EGFR Mutation-Positive Patients with T790M Mutation-Negative Acquired Resistance

Play Episode Listen Later Nov 20, 2015 3:24

Dr. Jack West reviews treatment options for patients with an EGFR activating mutation and acquired resistance but no T790M mutation, focusing on a clinical trial with the novel hypoxia-induced pan-HER inhibitor TH4000.

growth west positive cancer institute trial patients resistance trials negative options swedish factor clinical lung mutation clinical trials acquired receptor inhibitor egfr nsclc jack west epidermal osimertinib gracecast t790m cancergrace acquired resistance nonsmall azd9291 panher co1686 rociletinib th4000

Clinical Trial Spotlight: Options for EGFR Mutation-Positive Patients with T790M Mutation-Negative Acquired Resistance

Play Episode Listen Later Nov 20, 2015 3:24

Dr. Jack West reviews treatment options for patients with an EGFR activating mutation and acquired resistance but no T790M mutation, focusing on a clinical trial with the novel hypoxia-induced pan-HER inhibitor TH4000.

growth west positive cancer institute trial patients resistance trials negative options swedish factor clinical lung mutation clinical trials acquired receptor inhibitor egfr nsclc jack west epidermal osimertinib gracecast t790m cancergrace acquired resistance nonsmall azd9291 panher co1686 rociletinib th4000

Clinical Trial Spotlight: Should a Third Generation EGFR Inhibitor be First Line Therapy for EGFR Mutation-Positive NSCLC?

Play Episode Listen Later Nov 12, 2015 5:09

Dr. Jack West introduces the question of whether third generation EGFR tyrosine kinase inhibitors osimertinib and rociletinib should be used as first line therapy rather than for acquired resistance, including discussing key clinical trials on the topic.

growth west positive therapy cancer institute trial trials swedish factor clinical lung mutation clinical trials receptor first line inhibitor egfr third generation nsclc jack west epidermal osimertinib flaura gracecast cancergrace nonsmall azd9291 rociletinib co1686

Clinical Trial Spotlight: Should a Third Generation EGFR Inhibitor be First Line Therapy for EGFR Mutation-Positive NSCLC?

Play Episode Listen Later Nov 12, 2015 5:09

Dr. Jack West introduces the question of whether third generation EGFR tyrosine kinase inhibitors osimertinib and rociletinib should be used as first line therapy rather than for acquired resistance, including discussing key clinical trials on the topic.

growth west positive therapy cancer institute trial trials swedish factor clinical lung mutation clinical trials receptor first line inhibitor egfr third generation nsclc jack west epidermal osimertinib flaura gracecast cancergrace nonsmall azd9291 rociletinib co1686

Clinical Trial Spotlight: Should a Third Generation EGFR Inhibitor be First Line Therapy for EGFR Mutation-Positive NSCLC?

Play Episode Listen Later Nov 12, 2015 5:09

Dr. Jack West introduces the question of whether third generation EGFR tyrosine kinase inhibitors osimertinib and rociletinib should be used as first line therapy rather than for acquired resistance, including discussing key clinical trials on the topic.

growth west positive therapy cancer institute trial trials swedish factor clinical lung mutation clinical trials receptor first line inhibitor egfr third generation nsclc jack west epidermal osimertinib flaura gracecast cancergrace nonsmall azd9291 rociletinib co1686

The Potential Value of Repeat Biopsies in Acquired Resistance

Play Episode Listen Later Oct 25, 2015 2:19

MSKCC medical oncologist Dr. Greg Riely explains the growing value of a repeat biopsy after the development of acquired resistance in patients with an EGFR mutation.

growth resistance factor memorial repeat progression isolated mutation acquired receptor biopsies egfr sloan kettering epidermal mskcc riely gracecast t790m cancergrace acquired resistance greg riely oligoprogression gcvl gcvllung azd9291 co1686 rociletinib merelitinib

The Potential Value of Repeat Biopsies in Acquired Resistance

Play Episode Listen Later Oct 25, 2015 2:19

MSKCC medical oncologist Dr. Greg Riely explains the growing value of a repeat biopsy after the development of acquired resistance in patients with an EGFR mutation.

growth resistance factor memorial repeat progression isolated mutation acquired receptor biopsies egfr sloan kettering epidermal mskcc riely gracecast t790m cancergrace acquired resistance greg riely oligoprogression gcvl gcvllung azd9291 co1686 rociletinib merelitinib

The Potential Value of Repeat Biopsies in Acquired Resistance